Spectral AI Appoints Darcy Bajko CCO to Lead FDA-De Novo Cleared DeepView Burn System Sales
MDAI•Spectral AI appointed veteran Darcy Bajko as Chief Commercial Officer effective July 31, 2026 to spearhead global sales of its FDA De Novo-cleared DeepView System for burn indication. The Company targets first commercial sales by year-end 2026, leveraging her record of launching three FDA-cleared imaging platforms and building revenue streams.
1. Appointment of Chief Commercial Officer
Spectral AI announced the appointment of Darcy Bajko as Chief Commercial Officer, effective July 31, 2026. Bajko brings over two decades of commercial leadership at medical device companies including Integra LifeSciences and Smith+ Nephew, most recently serving as Vice President of Commercialization at MediView XR.
2. Commercial Launch and Revenue Goals
Bajko will lead the global sales launch of the DeepView System for burn indication, aiming to close the first commercial deals by year-end 2026. Her mandate includes building a high-performing sales and marketing team, driving clinical adoption in burn centers and emergency departments, and establishing a durable commercial revenue stream.
3. DeepView System Technology
The DeepView System combines multispectral imaging with a proprietary AI algorithm to assess burn wound healing potential in under 25 seconds. It secured FDA De Novo classification in May 2026 after training on a database of over 340 billion pixels, providing immediate, data-driven treatment insights to physicians.
